Ardelyx, Inc. (ARDX) AI Stock Analysis

Ardelyx, Inc. is a biopharmaceutical company founded in 2007 and based in Waltham, Massachusetts. The firm focuses on discovering, developing, and commercializing treatments for cardiorenal and gastrointestinal diseases. Its primary product candidate is tenapanor, which is in Phase III clinical trials targeting irritable bowel syndrome with constipation as well as hyperphosphatemia in chronic kidney disease patients on dialysis. Ardelyx is also developing RDX013, a potassium secretagogue for hyperkalemia, and RDX020, an early-stage program targeting metabolic acidosis in chronic kidney disease patients. The company commercializes tenapanor internationally through strategic partnerships with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada.

Ardelyx expanded annual revenue from $10.1M in FY2021 to $407.3M in FY2025, producing a 5-year revenue compound annual growth rate of 121.9%. Revenue grew 22.1% in FY2025 following a 168.1% surge in FY2024 to $333.6M. Gross margin stood at 89.5% in FY2025, up from 84.8% in FY2024. However, the company has operated at a loss across all reported years, posting an operating margin of -10.1% and net income of -$61.6M in FY2025. In the trailing twelve months ending June 30, 2026, revenue totaled $450.9M, quarterly revenue grew 23.8% year over year, and diluted EPS was -$0.23.

As of June 30, 2026, Ardelyx held $281.8M in cash and short-term investments alongside total debt of $256.2M, leaving net cash of $25.6M. Total assets were $575.9M and shareholders' equity was $149.0M, resulting in a debt-to-equity ratio of 1.72 and a current ratio of 3.34. The company generated negative operating cash flow of -$42.5M and free cash flow of -$44.0M in FY2025. Capital expenditures totaled $1.5M for FY2025, while the company's share count increased 115.2% over 5 years.

At a share price of $3.09 and a market capitalization of $797.8M, Ardelyx trades at a forward P/E of 9.9x, which sits below the 17.3x median of its US-listed Healthcare peers. Its price-to-sales multiple of 1.8x is also below the peer group median of 4.1x, while its EV-to-EBITDA multiple of 130.9x is well above the peer median of 12.0x. Over the past year, the stock declined 38.8%, underperforming the S&P 500 return of 16.8%. Over a 5-year period, the stock gained 186.1% compared to 83.0% for the index.

Ardelyx carries 10 Strong Buy ratings and 1 Buy rating from analysts, with no Hold, Sell, or Strong Sell recommendations. The mean price target of $12.90 implies an upside of 317.5% over the last close of $3.09. For the current fiscal year ending December 31, 2026, consensus estimates project an EPS of -$0.19 on revenue of $488.7M. For the next fiscal year, 8 analysts project revenue of $624.1M and EPS of $0.29. Ardelyx beat EPS estimates in 2 of the last 4 quarters, with its next earnings date scheduled for October 29, 2026.

This page is an AI-written research summary of Ardelyx, Inc. (ARDX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ARDX income statement, ARDX balance sheet, ARDX key metrics, ARDX analyst forecast, ARDX chart. See the ARDX stock overview for the latest quote and news.